Core Insights - The Ruijin Hainan Hospital has successfully implemented 186 licensed medical device projects, 2 special medical foods, and 5 biomedical new technologies by the end of September this year, benefiting over 26,800 patients [1] - The unique drug Vusonatide, which treats achondroplasia, completed its first treatment in China at this hospital less than a year after its launch in the EU [1] - The hospital aims to leverage its public hospital platform to enhance the regional medical ecosystem and promote high-quality development of the healthcare industry in Hainan Free Trade Port, with a goal to serve nationwide and radiate to Southeast Asia [1] Group 1 - The hospital's achievements in licensed medical projects demonstrate its capability in addressing the availability of innovative medical solutions [1] - The real-world research conducted by the hospital accelerates the process of effective and widespread use of international innovative drugs and devices in China [1] - The establishment of the national regional medical center aims to enhance healthcare services and innovation in the region [1]

Group 1 - The core viewpoint of the article highlights the target price increases for several listed companies, with notable gains for Kingsoft Office, Jiuzhou Pharmaceutical, and Zhongding股份 [1][2] - Kingsoft Office received a target price increase of 42.77%, with a highest target price of 432.90 yuan, rated as "Strong Buy" by Huachuang Securities [2][3] - Jiuzhou Pharmaceutical's target price increased by 33.88%, with a highest target price of 24.50 yuan, rated as "Buy" by Tianfeng Securities [2][3] - Zhongding股份 saw a target price increase of 33.27%, with a highest target price of 29.00 yuan, rated as "Buy" by CITIC Securities [2][3] Group 2 - On December 9, a total of 10 listed companies received recommendations from securities firms, including China Tianying and Hars, each receiving one recommendation [2] - Four companies received initial coverage on December 9, including China Tianying rated "Increase" by Guotai Junan Securities, Hars rated "Buy" by Guosheng Securities, Jiuzhou Pharmaceutical rated "Buy" by Tianfeng Securities, and Igor rated "Buy" by Zheshang Securities [3][4] - The industries represented among the newly covered companies include environmental governance, household goods, medical services, and other electronics [4]

Group 1 - Multiple factors support the performance of Chinese equities, maintaining a tactical overweight view on A/H shares [1] - The broad deficit is expected to further expand in 2026, with more proactive economic policies anticipated [1] - If the Federal Reserve lowers interest rates in December, the current stability and appreciation of the RMB will provide favorable conditions for monetary easing in early 2026 [1] Group 2 - November export growth rebounded more than expected, influenced by base effects and resilient demand [2] - The manufacturing PMI new export orders significantly recovered in November, with all sectors showing improvement [2] - Leading indicators suggest a stable external demand environment, with the electronic supply chain likely to continue supporting growth [2]

□ 本报记者 安莹 王甜 凌晨两点，39岁的南京市民王薇（化名）再次从浅睡中惊醒，她刷了刷手机，还是没有睡意。白天的会 议、未完成的业绩像电影般在脑中回放。这已经是她连续第七个失眠的夜晚。"我知道该睡了，但大脑 就像一台关不掉的机器。"她苦笑着说。刚刚过去的周末，王薇来到南京一家医院的睡眠门诊寻求帮 助。 来自江苏省卫生健康委的数据显示：截至目前，全省已有163家医院开设睡眠门诊，从三甲医院到社区 卫生服务中心，一个多层次、广覆盖的睡眠诊疗体系初步形成，多学科联手护"一夜好眠"。 为什么睡不好的人这么多 每周四、周五上午，南通大学附属医院神经内科的睡眠门诊外，总是坐满了人。"一周差不多要看近百 个病人。"神经内科主任医师曹茂红教授说。从二十岁出头熬夜加班的年轻人，到半夜总醒的老年人， 各个年龄层的都有。"主要是失眠、焦虑，还有打呼噜打得特别厉害的、睡觉时手脚乱动的。" 为什么现在睡不好的人这么多？"很多人认为失眠就是晚上睡不着，其实睡眠障碍是一个复杂的医学问 题。"曹茂红指出。现代睡眠医学将睡眠障碍分为失眠障碍、睡眠相关呼吸障碍、中枢性嗜睡、昼夜节 律紊乱、异态睡眠、睡眠相关运动障碍等七大类。"有的人是心理问 ...

每经AI快讯，据港交所12月9日披露，明基医院集团股份有限公司(简称：明基医院)通过港交所主板上 市聆讯，中金公司（601995）、花旗为联席保荐人。 ...

Core Viewpoint - Southbound funds have significantly increased their holdings in Hai Ji Ya Medical, indicating strong investor interest in the company [1] Group 1: Southbound Fund Activity - On December 9, southbound funds increased their holdings by 351,800 shares of Hai Ji Ya Medical (06078.HK) [1] - Over the past five trading days, there have been four days of net increases, totaling 1,407,400 shares [1] - In the last 20 trading days, there were 13 days of net increases, amounting to 6,962,000 shares [1] - As of now, southbound funds hold 212 million shares of Hai Ji Ya Medical, representing 34.22% of the company's issued ordinary shares [1] Group 2: Company Overview - Hai Ji Ya Medical Holdings Limited primarily provides medical services through two business segments [2] - The hospital business segment offers comprehensive oncology diagnosis and treatment services, including radiotherapy, chemotherapy, surgery, and targeted therapy [2] - The company gradually covers all stages of cancer diagnosis, treatment, and rehabilitation [2] - The other business segment focuses on various other operations [2] - The company mainly operates in the domestic market [2]

Core Viewpoint - Southbound funds have reduced their holdings in Jinxin Fertility (01951.HK) by 11.989 million shares on December 9, indicating a trend of net selling over recent trading days [1] Group 1: Southbound Fund Activity - In the last 5 trading days, southbound funds have reduced their holdings for 5 days, with a total net reduction of 24.8715 million shares [1] - Over the past 20 trading days, there have been 13 days of net increases in holdings by southbound funds, totaling a net increase of 9.3238 million shares [1] - Currently, southbound funds hold 1.46 billion shares of Jinxin Fertility, accounting for 52.94% of the company's issued ordinary shares [1] Group 2: Company Overview - Jinxin Fertility Medical Group Limited is an investment holding company primarily providing in vitro fertilization (IVF) services [1] - The company offers assisted reproductive services, management services, ambulatory surgical center facility services, auxiliary medical services, obstetrics and pediatrics medical services, as well as sales of medical consumables and equipment [1] - Jinxin Fertility operates mainly in China and the United States [1]

Group 1 - The core viewpoint of the news is that southbound funds have reduced their holdings in Yonghe Medical (02279.HK) by 5,000 shares on December 9, with a total net reduction of 47,000 shares over the past five trading days and 513,500 shares over the past 20 trading days [1] - As of now, southbound funds hold 16.412 million shares of Yonghe Medical, accounting for 3.12% of the company's total issued ordinary shares [1] Group 2 - Yonghe Medical Group Limited is a holding company specializing in providing hair-related medical services, offering a one-stop solution that includes hair transplant medical services, medical hair care, routine maintenance, and other supporting services [2] - The company has established a brand matrix centered around "Yonghe Medical," which includes professional hair transplant brand "Yonghe Hair Transplant," medical hair care brand "Shiyunxun," female aesthetic hair transplant brand "Yonghe Hair Origin," and medical wig brand "Hafada" [2] - Yonghe Medical has set up independent Shiyunxun Medical Hair Care Centers to provide medical testing, diagnosis, and personalized care treatment for patients troubled by hair issues, aiming to offer more professional medical hair health management services [2]

西维斯健康(CVS.US)涨近5%，报80.3美元。消息面上，西维斯健康提高全年盈利预期，目前预计每股 收益将在6.6至6.7美元之间。该公司强调2026年利润有望在监管等多重压力之下持续扩张，预计调整后 每股收益最高将达到7.2美元，高于分析师平均预期的7.17 美元。(格隆汇) ...

固生堂回购明细 | 日期 | 回购股数 | 回购最高价 | 回购最低价 | 回购金额 | | --- | --- | --- | --- | --- | | | （万股） | （港元） | （港元） | （万港元） | | 2025.12.09 | 34.01 | 28.400 | 28.020 | 959.73 | | 2025.12.08 | 22.06 | 28.480 | 27.860 | 622.16 | | 2025.12.05 | 18.60 | 28.460 | 28.460 | 529.36 | | 2025.12.04 | 20.00 | 28.680 | 28.420 | 571.93 | | 2025.12.03 | 32.00 | 28.980 | 28.520 | 919.33 | | 2025.12.02 | 37.84 | 29.380 | 28.700 | 1094.52 | | 2025.11.28 | 28.76 | 30.000 | 29.620 | 858.54 | | 2025.11.27 | 30.91 | 29.920 | 29.440 | 920.00 | | ...